68Ga-Trivehexin PET/CT在头颈部鳞状细胞癌和胰腺导管腺癌患者中的潜在疗效及αvβ6整合素表达免疫组化验证
该先导研究纳入32例疑似头颈部鳞状细胞癌(n=20)或胰腺导管腺癌(n=12)患者,分别行68Ga-Trivehexin PET/CT与18F-FDG PET/CT,并以免疫组化验证αvβ6整合素表达。68Ga-Trivehexin在胰腺导管腺癌9例中8例、头颈部鳞状细胞癌18例中17例显示摄取增高,且与免疫组化表达相关;对原发和转移灶检测的敏感性、特异性、准确性高于18F-FDG PET。作者认为68Ga-Trivehexin是有前景的无创分子影像剂。
要点
- 68Ga-Trivehexin在胰腺导管腺癌9例中8例、头颈部鳞状细胞癌18例中17例显示摄取增高。
- 2例疑似复发炎性改变者18F-FDG PET摄取增高(7.98±3.1),68Ga-Trivehexin无明显摄取(2.2±0.34)。
- 免疫组化αvβ6整合素表达越高,68Ga-Trivehexin摄取越高;其检测原发和转移灶的敏感性、特异性、准确性高于18F-FDG PET。
核心结论
- 68Ga-Trivehexin是一种有前景的无创分子影像剂,适用于表达αvβ6整合素的肿瘤,尤其在18F-FDG PET/CT因摄取低或肿瘤部位周围非特异性摄取而可能欠佳时。
研究设计与样本
- 先导研究,纳入32例疑似头颈部鳞状细胞癌(n=20)或胰腺导管腺癌(n=12)患者,在2个不同日期分别行全身68Ga-Trivehexin PET/CT和18F-FDG PET/CT。
- 全部32例均行肿瘤部位活检用于组织病理学诊断及αvβ6整合素免疫组化,免疫组化表达程度采用免疫反应评分和改良4点免疫反应评分分类。
主要发现
- 胰腺导管腺癌9例中8例,68Ga-Trivehexin PET显示原发和转移灶摄取增高(平均SUVmax 5.9±3.3),病灶 delineation 良好;18F-FDG PET在7例中显示摄取增高(6.2±2.6)。
- 头颈部鳞状细胞癌18例中17例,68Ga-Trivehexin摄取增高(6.6±4.5),18F-FDG摄取增高(12.7±6.7)。
- 2例疑似疾病复发的炎性改变者,18F-FDG PET摄取增高(7.98±3.1),68Ga-Trivehexin PET无明显摄取(2.2±0.34)。
- 免疫组化显示,68Ga-Trivehexin摄取较高的病灶αvβ6整合素表达较高。
- 68Ga-Trivehexin PET检测原发和转移灶的敏感性、特异性、准确性高于18F-FDG PET。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: αvβ6 integrin is exclusively expressed in epithelial cells and is upregulated in many carcinomas, such as pancreatic ductal adenocarcinomas (PDACs) and head and neck squamous cell carcinomas (H&NSCCs). Trivehexin is a recently synthesized trimerized αvβ6 integrin selective nonapeptide, which can be labeled with a positron emitter like 68 Ga. This is a pilot study to assess the potential role of 68 Ga-Trivehexin PET/CT in patients with H&NSCC and PDAC and their correlation with αvβ6 integrin expression by the tumor tissue on immunohistochemistry (IHC). PATIENTS AND METHODS: Thirty-two patients with suspected H&NSCC (n = 20) or PDAC (n = 12) underwent whole-body 68 Ga-Trivehexin PET/CT and 18 F-FDG PET/CT scans on 2 separate days. All 32 patients underwent biopsy from the tumor site for histopathological diagnosis and IHC for αvβ6 integrin expression. The degree of αvβ6 integrin expression on IHC was scored using the immunoreactive score and modified 4-point immunoreactive score classification. RESULTS: The 68 Ga-Trivehexin PET images demonstrated increased tracer uptake (mean SUV max 5.9 ± 3.3) in the primary and metastatic lesions with good lesion delineation in 8 out of the 9 cases of PDACs. However, FDG PET showed increased tracer uptake in 7 cases (6.2 ± 2.6). Among various cases of H&NSCC, increased uptakes of 68 Ga-Trivehexin (6.6 ± 4.5) and 18 F-FDG (12.7 ± 6.7) were seen in 17 out of the 18 patients. The 2 cases of inflammatory changes with suspected disease recurrence showed increased tracer uptake in 18 F-FDG PET (7.98 ± 3.1) and no significant uptake in 68 Ga-Trivehexin PET (2.2 ± 0.34).IHC showed higher expression of αvβ6 integrins in lesions with higher uptake of 68 Ga-Trivehexin. A higher sensitivity, specificity, and accuracy of 68 Ga-Trivehexin PET over 18 F-FDG PET was seen for detection of primary and metastatic lesions. CONCLUSIONS: 68 Ga-Trivehexin is a promising noninvasive molecular imaging agent for tumors expressing αvβ6 integrin, especially in cases where 18 F-FDG PET/CT scan may be suboptimal due to its low uptake, or due to its nonspecific uptake around tumor sites.
引用
- Das SS, Ahlawat S, Thakral P, et al. Potential Efficacy of 68 Ga-Trivehexin PET/CT and Immunohistochemical Validation of αvβ6 Integrin Expression in Patients With Head and Neck Squamous Cell Carcinoma and Pancreatic Ductal Adenocarcinoma. Clin Nucl Med. 2024. PMID: 38768077. doi:10.1097/RLU.0000000000005278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。